Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 2728667-27-2
2. N-(1-(8-((3-methyl-4-((1-methyl-1h-benzo[d]imidazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperidin-4-yl)acrylamide
3. Bi1810631
4. Bi-1810631
5. N-[1-[4-[3-methyl-4-(1-methylbenzimidazol-5-yl)oxyanilino]pyrimido[5,4-d]pyrimidin-6-yl]piperidin-4-yl]prop-2-enamide
6. Zongertinib?
7. Zongertinib [inn]
8. Drh7r67uvl
9. Zongertinib [usan]
10. Zongertinib (jan/usan/inn)
11. Chembl5314498
12. Schembl23957509
13. Gtpl12387
14. Wlz3778
15. Glxc-27939
16. Ex-a8033
17. Nsc854531
18. Nsc-854531
19. Da-59312
20. Ts-09568
21. Example I-01 [wo2021213800a1]
22. Hy-148810
23. Cs-0641245
24. D12879
25. G65208
26. 2-propenamide, N-[1-[8-[[3-methyl-4-[(1-methyl-1h-benzimidazol-5-yl)oxy]phenyl]amino]pyrimido[5,4-d]pyrimidin-2-yl]-4-piperidinyl]-
27. N-[1-(8-{3-methyl-4-[(1-methyl-1h-1,3-benzimidazol-5- Yl)oxy]anilino}pyrimido[5,4-d]pyrimidin-2-yl)piperidin-4- Yl]prop-2-enamide
Molecular Weight | 535.6 g/mol |
---|---|
Molecular Formula | C29H29N9O2 |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 7 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 123 |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 870 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
17
PharmaCompass offers a list of Zongertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zongertinib manufacturer or Zongertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zongertinib manufacturer or Zongertinib supplier.
PharmaCompass also assists you with knowing the Zongertinib API Price utilized in the formulation of products. Zongertinib API Price is not always fixed or binding as the Zongertinib Price is obtained through a variety of data sources. The Zongertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Zongertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zongertinib, including repackagers and relabelers. The FDA regulates Zongertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zongertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zongertinib supplier is an individual or a company that provides Zongertinib active pharmaceutical ingredient (API) or Zongertinib finished formulations upon request. The Zongertinib suppliers may include Zongertinib API manufacturers, exporters, distributors and traders.
click here to find a list of Zongertinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zongertinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Zongertinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Zongertinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Zongertinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zongertinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Zongertinib suppliers with NDC on PharmaCompass.
Zongertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zongertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zongertinib GMP manufacturer or Zongertinib GMP API supplier for your needs.
A Zongertinib CoA (Certificate of Analysis) is a formal document that attests to Zongertinib's compliance with Zongertinib specifications and serves as a tool for batch-level quality control.
Zongertinib CoA mostly includes findings from lab analyses of a specific batch. For each Zongertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zongertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Zongertinib EP), Zongertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zongertinib USP).